Navigation Links
Hepatitis B Vaccine - Comprehensive Patent Search
Date:8/4/2011

NEW YORK, Aug. 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Hepatitis B Vaccine - Comprehensive patent search

http://www.reportlinker.com/p0366285/Hepatitis-B-Vaccine---Comprehensive-patent-search.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Eliminate unnecessary risk with the industry benchmark in comprehensive patent information.

Pipeline Developer is a regularly updated, professional patent search performed by our expert team, which not only identifies relevant patents, but delivers categorisation and interpretation, all delivered by a convenient online interface.

This Pipeline Developer report covers Hepatitis B Vaccine

Hepatitis B Vaccine indications: Vaccine against Hepatitis B

Hepatitis B Vaccine innovator: GlaxoSmithKline (Engerix B, HBvaxPro); Merck (H-B-Vax II)

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.

Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on. And that means your staff can concentrate on how the patent landscape affects your business, rather than trying to source reliable patent information.

Pipeline Developer features:

# Comprehensive patent searching, covering the world's key territories (see 'search coverage' below)

# Identifies patents covering molecule, formulation, process, use, combination and assay techniques (see 'Patent Categories Identified'below)

# Patent identification, categorisation and interpretation

# Grouped by patent family and assigned to development categories based on Interpretation of key aspects of the patent claims

# Manual filtration of patents not relevant to generic development

# Updated on a monthly basis, including changes to patent families, statuses, and litigation

# Enables fast analysis and verification by hyper-linking to crucial patent documents and national registers

Patent Categories Identified:

1. Molecular Form

a) Molecule Patents

b) Salts, Hydrates & Solvates

c) Polymorphic Forms

d) Other Molecular Forms

2. Active Ingredient Preparation

a) Intermediates & Preparation Thereof

b) Final Synthetic Stages

c) Complete Synthesis

d) Purification Methods

e) Fermentation Methods

f) Biotechnology

3. Formulations & Methods Thereof

a) General Formulations & Methods

b) Injectable Formulations

c) Oral Formulations

d) Other Administration-Specific Formulations

e) Excipients, Kits & Packaging

4. Related Medical Use & Administration

a) New Use Related to Main Indication

b) Dosing Regimen/Administration Conditions

5. Active Ingredient Combinations

a) Novel Combinations

b) Use of Combinations

c) Dosing Regimen & Administration Conditions for Combinations

6. Analytical Methods

a) Assaying Methods

b) Methods of Determining Patient Suitability

Search coverage:

Clicking on a patent family displays detailed information on the 'Core' and 'Non-Core' 'Patent Family Equivalents'. 'Core Patent Family Equivalents' are equivalent patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents. Statuses are also monitored and updated. 'Extended Patent Family Equivalents' are equivalent patents found through the INPADOC database, increasing the search coverage to 70 countries.

Patent and national register access:

Clicking on a listed patent/application number or text or image link will launch a pop-up window containing an image of the patent, enabling easy analysis of the patent documents. Clicking on a register link launches a pop-up window with the patent office register extract for that patent. This allows investigation into the examination status of a pending patent, opposition of a granted patent and/or payment of maintenance fees. Please note that no extra charges apply to accessing or downloading documents of any kind.

Litigation alerts:

Informing you of developments in court, litigation alerts can also be accessed by clicking on the litigation symbol next to the status, with links to judgements where available.

Updating:

To take the time and hassle out of monitoring and updating a large number of patents, all Pipeline Developer reporting is updated on a monthly basis. Convenient change flags identify new patent families, new patent family members, changes in statuses and litigation alerts.

Legal status and transaction history:

You can also find legal status and transaction history for 'Extended Patent Family Equivalents' by clicking on the INPADOC Family/Legal Status button for 65 additional territories.

Reporting and access:

All data can be exported into Microsoft Excel and print friendly versions for ease of data manipulation and reporting. Company details are confidential and all data is SSL secure. Five users per company are permitted and access levels are controlled by a nominated 'company administrator'.

Pipeline Developer is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite.

Eliminate unnecessary risk with the industry benchmark in comprehensive patent information.

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait. Used by the world's leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on. And that means your staff can concentrate on how the patent landscape affects your business, rather than trying to source reliable patent information.

To order this report:

Drug and Medication Industry: Hepatitis B Vaccine - Comprehensive patent search

Drug and Medication Business News

More  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Drug in New Hepatitis C Clinical Trial
3. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
6. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
7. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
8. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
9. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
10. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... N.J., Dec. 8, 2016 CANTEL MEDICAL CORP. (NYSE: ... of $18,800,000, or $0.45 per diluted share, on a 22.1% ... quarter ended October 31, 2016. This compares with net income ... $153,779,000 for the first quarter ended October 31, 2015. ... quarter ended October 31, 2016 to $21,323,000, or $0.51 per ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... with cutting edge next-generation sequencing and bioinformatics expertise; AITbiotech Pte ... the Genome Institute of Singapore (GIS) ... joint venture between Novogene and AITbiotech – will establish a ... Singapore .   The new centre will ...
(Date:12/7/2016)... Dec. 7, 2016   IQuity, Inc., a ... Don Hardison has been appointed to ... executive with extensive experience as CEO, COO, and ... 500 companies within the molecular, clinical diagnostic, and ... and sales experience within the pharmaceutical industry. His ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... California Senate ... medical payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ ... Research Institute (WCRI) . , According to the study, medical payments per claim in ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael ... headquartered in Hamilton County, is embarking on a charity drive with the aim ... new homes for orphaned or neglected senior dogs in the Cincinnati region, and ...
(Date:12/8/2016)... Fort Payne, AL (PRWEB) , ... December 08, ... ... enterprise offering insurance and financial consulting services to residential and commercial clients in ... raise awareness and support for Nobis Works. , Since 1977, Nobis Works has ...
(Date:12/7/2016)... Wisconsin (PRWEB) , ... December 07, 2016 , ... Kenall ... extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire ... right amount of light where and when it’s needed. , A 2’ ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... (“Presence”) for a purchase price of approximately $17.4 million (net of the ... revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is a ...
Breaking Medicine News(10 mins):